

ARTICLE

Stereoselective innovative synthesis and biological evaluation of new real carba analogues of minimal epitope $\text{Man}\alpha(1,2)\text{Man}$ as DC-SIGN inhibitors

Cite this: DOI: 10.1039/x0xx00000x

Received 00th January 2012,

Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

Vittorio Bordoni,^a Vanessa Porkolab,^b Sara Sattin,^c Michel Thépaut,^b Ileana Frau,^a Lucilla Favero,^a Paolo Crotti,^a Anna Bernardi,^c Franck Fieschi,^b Valeria Di Bussolo^{*d}

Antagonists of the C-type lectin DC-SIGN are promising therapeutic agents against viruses and bacteria. The development of glycomimetics ligands for DC-SIGN has so far proved to be challenging, since this membrane-protein presents four carbohydrate-binding domains (CRD) that specifically recognize mannose and fucose. In the recent past, we were able to develop inhibitors mimicking the minimal natural epitope $\text{Man}\alpha(1,2)\text{Man}$ using a mannoside with conformationally restricted dimethyl cyclohexandicarboxylate-based aglycons designed to exploit the high enzymatic stability and to generate multivalent or solid supported systems as potent lectin ligands. Herein we describe the innovative synthesis of a different class of pseudodisaccharides, mimic of the natural $\text{Man}\alpha(1,2)\text{Man}$ moiety, characterized by the presence of a real D-carbamannose unit instead of a simpler mimic structure. Their chemical synthesis and biological activity using an SPR inhibition assay are reported. These pseudodisaccharides display inhibition values similar to those of the natural disaccharide $\text{Man}\alpha(1,2)\text{Man}$, with a good affinity for DC-SIGN and can be considered as possible candidates for further structural modifications towards improved inhibitors.

Introduction

A broad range of biological processes including cellular adhesion, signaling, migration and infection are mediated by carbohydrate-lectin interactions.¹⁻⁴ In this framework, DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3 (ICAM-3)-Grabbing Non-integrin) is a C-type lectin involved in the recognition of viruses and pathogens at the mucosal level. In particular the interaction between gp120 on the surface of HIV-1 and DC-SIGN allows the delivery of the virus to tissues rich in CD4^+ T cells, such as lymphoid organs, playing therefore a crucial role in the infection process at the mucosal level.^{5,6} The main carbohydrate ligand present on gp120 and recognized by the DC-SIGN carbohydrate-binding domains (CRDs) is the high mannose glycan $\text{Man}_9(\text{GlcNAc})_2$ (Man9, **1**, Figure 1). Therefore, derived glycomimetic structures can inhibit DC-SIGN action and are of high interest against HIV infections as antiviral agents.⁷⁻¹⁷ Notably, the 1,2-mannobioside disaccharide unit, $\text{Man}\alpha(1,2)\text{Man}$ **2** (Figure 1), contained in all three arms D1, D2 and D3 of Man9, is one of the minimal epitopes for binding to DC-SIGN. To underline the efficiency of this epitope and the importance of polyvalent systems, the incorporation of the natural 1,2-mannobioside into gold glyconanoparticles (Au-GNPs) increases the inhibitory activity by more than four orders of magnitude, compared to that of the monovalent disaccharide.¹⁸ We previously reported that

disaccharide mimetics **3a-c** (Figure 1) show three dimensional structure and conformational behavior comparable to those of $\text{Man}\alpha(1,2)\text{Man}$ **2** and display a micromolar activity against DC-SIGN mediated Ebola viral infection, to demonstrate for the first time that DC-SIGN antagonism by small molecules might be used to inhibit viral transfection mediated by DC-SIGN.^{10,17,19}




Fig. 1 High mannose glycan $\text{Man}_9(\text{GlcNAc})_2$ **1**, minimal epitope $\text{Man}\alpha(1,2)\text{Man}$ **2** and chemical structure of disaccharide mimetics **3a-c**.

Herein, we describe the innovative synthesis of pseudodisaccharides **4** and **5** (Figure 2), real carba analogues of the natural disaccharide epitope **2**, and their biological evaluation as prospective DC-SIGN ligands. In our approach, the non reducing portion of the natural disaccharide

Man α (1,2)Man is replaced by a carbasugar, in view of an improved drug-like character of the resulting glycomimetic compared to the natural carbohydrate. Indeed, sugar mimics are generally more soluble and membrane penetrant, less hydrophilic and less metabolically labile than the sugars themselves.²⁰





Fig. 2 Chemical structures of pseudodisaccharides **4** and **5** real carba analogues of epitope **2**.

Results and discussion

Synthesis of pseudodisaccharides **4** and **5**.


The stereoselective synthesis of pseudodisaccharides **4** and **5** proceeds through the construction of skeleton **8** (Scheme 1) by glycosylation of the new carbamannose glycosyl acceptor **7** with tetrabenzoyl mannose trichloroacetimidate **6** as typical glycosyl donor.²¹



Scheme 1 Stereoselective synthesis of skeleton **8**.


Two carbamannose units **15** and **16**, carrying either acetyl or benzyl protecting groups, were prepared and studied in this reaction. Both were prepared starting from the pivotal carba epoxy diol **11** obtained from *m*-CPBA epoxidation of cyclohexene **10** in turn prepared from tri-*O*-acetyl-D-glucal **9**,²² as shown in Scheme 2.

The allyl alcohol **10** is epoxidized stereoselectively by MCPBA, which reacts with the double bond face in *syn* to the allylic hydroxy group.^{23,24} Key epoxide **11** was then separately elaborated to give tri-*O*-benzyl-5a-carba- β -epoxide (+)-**14**²⁵ upon treatment with NaH/BnBr in DMF, or debenzylated at C(6), under reductive conditions with H₂/(10%)Pd-C, to afford β -epoxy triol **12** which was *in situ* acetylated (Ac₂O/Py), to give tri-*O*-acetyl-5a-carba- β -epoxide (+)-**13**²⁵ (Scheme 2). Epoxides (+)-**13** and (+)-**14** represent the *carbapglycosylating agents* which were subjected to ring opening reaction with freshly prepared 1.3M 2-azido-1-ethanol in CH₂Cl₂²⁶ in the presence of a catalytic amount of Cu(OTf)₂ as the Lewis acid catalyst.²⁷ In accordance with reports by Ogawa and Cumpstey^{28,29} on the behavior of 1,2-epoxides with β -manno configuration like (+)-**13** and (+)-**14**, nucleophilic attack exclusively occurs in a *trans*-diaxial fashion, at the less sterically hindered and more electronically favored oxirane C(1) carbon. This way, the corresponding 2-azido-1-ethoxy-cyclohexanol derivatives (+)-**15** from (+)-**13**,



Scheme 2 Stereoselective synthesis of carbamannose glycosyl acceptor **15** and **16**.

and (+)-**16** from (+)-**14**, are obtained through a completely regio- and stereoselective ring opening process.



Scheme 3 Stereoselective synthesis of glycoconjugates (-)-**4** and (+)-**5**.

Glycosylation reaction of glycosyl acceptors (+)-**15** and (+)-**16** by the typical mannosyl donor **6** was successfully carried out in standard conditions (TMSOTf in CH₂Cl₂, -20 °C, 2h), to afford glycoconjugates (-)-**17** and (-)-**18** in a completely α -

stereoselective fashion. Catalytic hydrogenolysis of (-)-**18** reduced the azido functionality and removed the benzyl protecting groups to afford pseudodisaccharide (-)-**19**. Subsequent Zemplén deprotection provided the final pseudodisaccharide (+)-**5** with a α -aminoethoxy chain at pseudoanomeric C(1) in 69% yield after recrystallization from *i*-Pr₂O. On the other hand, Zemplén deprotection of glycoconjugate (-)-**17**, afforded the α -azidoethoxy pseudodisaccharide (-)-**4** in 88% yield (Scheme 3).

Preparation of pseudodisaccharides (-)-**4** and (+)-**5** represents the first example of stereoselective synthesis of real carba analogues of minimal natural epitope Man α (1,2)Man thus, their biological activity as DC-SIGN antagonists was evaluated using an inhibition assay based on Surface Plasmon Resonance (SPR) technique.

DC-SIGN inhibition assays

The affinity of the newly synthesized sugar conjugates **4** and **5** for DC-SIGN was tested by competition experiments using surface plasmon resonance (SPR), as previously described.¹¹ A CM4 sensorchip was functionalized with mannosylated Bovine Serum Albumine (BSA-Mannotriose) and a fixed amount of the extracellular domain of DC-SIGN was injected over the surface with increasing concentrations of ligands. The natural 1,2-mannobioside **2** and its mimic **3** were used as control. From the inhibition curves (Fig. 3) and according to 4-parameter model, an IC₅₀ of about 1 mM was estimated for all the compounds. These data show that the new pseudodisaccharides (+)-**5** and (-)-**4** have inhibitory potency similar to the natural disaccharide Man α 1-2Man. The IC₅₀, extracted from inhibition curves are 964 \pm 14.6 μ M for **2**, 941 \pm 20.2 μ M for **3**, 1467 \pm 32.1 μ M for **4** and 1453 \pm 30.6 μ M for **5**. Thus, taking into account their enzymatic stability, (+)-**5** and (-)-**4** could be considered as possible candidates to prepare multivalent systems to be used as inhibitors of viral infection.




Fig. 3 Inhibition of DC-SIGN extracellular domain (DC-SIGN ECD) binding to immobilized mannosylated-bovine serum albumin (BSA) using surface plasmon resonance (SPR). A and B: Sensorgrams of DC-SIGN ECD inhibition by increasing concentrations of compound **4** and **5**, respectively, from 0 μ M to 5000 μ M. C: Comparison of the inhibitory potency of **2** (○), **3** (□), **4** (●), and **5** (■) toward the DC-SIGN ECD mannosylated-BSA interaction determined by competition assays.

Conclusions

We have successfully planned and achieved the innovative stereospecific synthesis of the two glycoconjugates (-)-**4** and (+)-**5**, which were intended to represent mimics of the natural Man α (1,2)Man moiety, characterized by the presence of a real D-carbamannose unit. These glycoconjugates were designed to mime the minimal natural epitope Man α (1,2)Man of the high mannose glycan Man₉(GlcNAc)₂, which is principal carbohydrate ligand recognized by the DC-SIGN. The biological assays evaluated using an inhibition (binding affinity?) assay based on Surface Plasmon Resonance (SPR) technique, displayed a remarkable activity of new pseudodisaccharides (-)-**4** and (+)-**5** having inhibitory potency similar to the natural disaccharide Man α 1-2Man. These results confirm the validity of the DC-SIGN antagonism by small molecules and pave the way to more extensive studies of enzymatically stable glycoconjugates that are useful to prepare efficient multivalent systems as DC-SIGN inhibitors.

Experimental

Materials and methods

All solvents and chemicals were used as purchased without further purification. Chromatographic separations were performed on silica gel columns by flash (Kieselgel 40, 0.040–0.063 mm; Merck) or by automated chromatography with Isolera® Biotage. Reactions were followed by thin-layer chromatography (TLC) on Merck aluminum silica gel (60 F₂₅₄) sheets that were visualized under a UV lamp. Evaporation was performed in vacuo (rotating evaporator). Sodium sulfate was always used as the drying agent. Melting points were determined with a Kofler hot-stage apparatus and are uncorrected. Optical rotations were measured with a ATAGO AP-300 Automatic Polarimeter at 25°C. Proton (¹H) and carbon (¹³C) NMR spectra were obtained with a Bruker Avance 250 MHz spectrometer using the indicated deuterated solvents. Chemical shifts are given in parts per million (ppm) (δ relative to residual solvent peak for ¹H and ¹³C). FTIR spectra were obtained with a IR Cary 600 FTIR (Agilent Technologies). Yields refer to isolated and purified products. High-resolution mass spectrometry (HRMS) analysis were performed using a Waters Xevo® G2-S QToF at Mass Spectrometry facility, PCN-ICMG of Grenoble. Compounds are dissolved in 1:1 acetonitrile/water (concentration 10E-5 M).

Synthetic procedures

6-*O*-Benzyl-1,2-anhydro-5a-carba- β -D-mannopyranose (11). MCPBA (0.627 g, 3.64 mmol, 1.2 equiv) was added to a solution of *trans* diol **10**²³ (0.709 g, 3.03 mol, 1.0 equiv) in anhydrous CH₂Cl₂ (17 mL) at 0°C and the reaction mixture was stirred at room temperature. After 18h, the reaction was diluted with CH₂Cl₂, the organic phase was washed with 10% aqueous Na₂S₂O₃, saturated aqueous NaHCO₃ and brine, dried (Na₂SO₄) and concentrated to afford a crude reaction product (0.585 g), which was subjected to a flash chromatography. Elution with 3:7 hexane/AcOEt mixture afforded β epoxide **11** (0.438 g, 59% yield), pure as a white solid: mp 86-88 °C. R_f = 0.13 (3:7 hexane/AcOEt). [α]_D²⁰ +8.03 (c 0.61, CHCl₃). FTIR (neat) ν 3360.2, 3255.3, 3026.3, 2920.5, 2852.6, 1453.5, 1362.3, 1257.7, 1112.6, 1057.9, 1015.3, 933.3, 731.7, 695.4 cm⁻¹. ¹H NMR (250 MHz; CDCl₃) δ 7.20 – 7.43 (m, 5H; Ar), 4.54 (d, *J* = 12.0 Hz, 1H; benzylic), 4.48 (d, *J* = 12.0 Hz, 1H; benzylic), 3.84 (dd, *J* = 8.2, 1.7 Hz, 1H; H₃), 3.61 (dd, *J* = 10.2, 8.3 Hz, 1H; H₄), 3.52 (dd, *J* = 9.2, 4.8 Hz, 1H; H₆), 3.47 (dd, *J* = 9.2, 4.8 Hz, 1H; H_{6'}), 3.37 (ddd, *J* = 4.0, 1.7, 0.6 Hz, 1H; H₂), 3.27 (t, *J* = 4.3 Hz, 1H; H₁), 2.00 – 2.12 (m, 1H; H_{5aa}), 1.79 – 1.95 (m, 1H; H₅), 1.73 (dd, *J* = 14.2, 11.2 Hz, 1H; H_{5a β}). ¹³C NMR (75 MHz; CDCl₃) δ 137.84, 128.63, 127.99, 127.78, 74.64, 73.52, 73.11, 72.24, 56.64, 53.30, 38.90, 26.39.

3,4,6-tri-*O*-benzyl-1,2-anhydro-5a-carba- β -D-mannopyranose (14).²⁵

A 60% dispersion of NaH (0.374 g, 9.36 mmol, 4.0 equiv) was added to a solution of β epoxide **11** (0.584 g, 2.34 mmol, 1.0 equiv) in anhydrous DMF (8 mL) at 0°C and the reaction mixture was stirred at the same temperature for 30 minutes and then at room temperature for 30 minutes. After cooling at 0°C, BnBr (0.70 mL, 5.86 mmol, 2.5 equiv) was added dropwise and the solution was stirred 2 h at room temperature. Dilution with Et₂O and ice and evaporation of the washed (brine) and dried (Na₂SO₄) organic solution afforded a crude reaction mixture (0.920 g), which was subjected to a flash chromatography. Elution with an 8:2 hexane/AcOEt mixture afforded tri-*O*-benzyl β epoxide **14** (0.740 g, 73% yield), pure as a white solid. mp 53-55 °C. R_f = 0.24 (8:2 hexane/AcOEt). [α]_D²⁰ +32.7 (c 0.81, CHCl₃). FTIR (neat) ν 3025.0, 2913.9, 2852.0, 1946.5, 1873.9, 1744.0, 1453.3, 1366.2, 1102.3, 1081.5, 1023.5, 930.9, 737.6, 695.5 cm⁻¹. ¹H NMR (250 MHz, CDCl₃) δ 7.27-7.45 (m, 14H; Ar), 7.20-7.25 (m, 1H; Ar), 4.84 (d, *J* = 10.4 Hz, 1H; benzylic), 4.82 (s, 2H; benzylic), 4.52 (d, *J* = 10.4 Hz, 1H; benzylic), 4.46 (s, 2H; benzylic), 3.83 (dd, *J* = 8.1, 1.9 Hz, 1H; H₃), 3.65 (dd, *J* = 10.9, 8.1 Hz, 1H; H₄), 3.45-3.55 (m, 2H; H₆ + H_{6'}), 3.34 (dd, *J* = 4.1, 1.8 Hz, 1H; H₂), 3.26 (t, *J* = 3.9 Hz, 1H; H₁), 1.97 – 2.20 (m, 2H; ; H_{5aa} + H_{5a β}), 1.90-1.63 (m, 1H; H₅). ¹³C NMR (75 MHz, CDCl₃) δ 139.1, 139.0, 138.9, 128.8, 128.7, 128.5, 128.3, 128.1, 128.0, 127.9, 81.9, 78.2, 75.6, 73.5, 72.8, 70.5, 55.7, 53.9, 40.3, 27.4.

(2-azidoethyl)-3,4,6-tri-*O*-benzyl-5a-carba- α -D-mannopyranoside (16).

Tri-*O*-benzyl β epoxide **14** (0.370 g, 0.859 mmol, 1 equiv) was dissolved in a solution 1.3 M 2-azido-1-ethanol in CH₂Cl₂ (2.65 mL, 3.44 mmol, 4.0 equiv) freshly prepared²⁵ and Cu(OTf)₂ (0.124 g, 0.344 mmol, 0.4 equiv) was added. The reaction mixture was stirred for 18 h at room temperature. Dilution with CH₂Cl₂ and evaporation of the washed (1:1 NaHCO₃/NH₄Cl mixture and brine) and dried (Na₂SO₄) organic solution afforded a crude reaction mixture (0.363 g) which was subjected to a flash chromatography. Elution with 7:3 hexane/AcOEt mixture afforded product **16** (0.304 g, 68% yield), pure as a pale yellow liquid. R_f = 0.50 (7:3 hexane/AcOEt); [α]_D²⁰ +22.34 (c 0.67, CHCl₃). FTIR (neat) ν 3449.6, 2927.2, 2871.8, 2103.9, 1737.6, 1284.4, 1242.6, 1109.5, 1048.3, 993.4, 731.3, 696.8 cm⁻¹. ¹H NMR (250 MHz; CDCl₃) δ 7.20-7.40 (m, 15H; Ar), 4.83 (d, *J* = 10.9 Hz, 1H; benzylic), 4.72 (d, *J* = 11.5 Hz, 1H; benzylic), 4.66 (d, *J* = 11.5 Hz, 1H; benzylic), 4.51 (d, *J* = 10.9 Hz, 1H; benzylic), 4.47 (s, 2H; benzylic), 4.13 (t, *J* = 3.4 Hz, 1H; H₁), 3.80 (dd, *J* = 9.0, 3.0 Hz, 1H; H₂), 3.45-3.75 (m, 6H), 3.18-3.39 (m, 2H; ; H₆ + H_{6'}), 1.95-2.14 (m, 1H; ; H₅), 1.85-1.92 (m, 2H; H_{5aa} + H_{5a β}).

¹³C NMR (63 MHz, CDCl₃) δ 139.11, 138.89, 138.53, 128.76, 128.68, 128.52, 128.51, 128.12, 128.11, 128.01, 127.74, 127.68, 127.64, 127.18, 82.39, 77.85, 77.08, 75.09, 73.18, 72.84, 70.59, 69.61, 68.27, 51.06, 37.37, 26.94.

(2-azidoethyl)-2-*O*-[2',3',4',6'-tetra-*O*-benzoyl- α -D-mannopyranosyl]-3,4,6-tri-*O*-benzyl-5a-carba- α -D-mannopyranoside (18).

Trichloroacetimidate **6**²¹ (0.208 g, 0.281 mmol, 1.3 equiv) and carbamnoside **16** (0.112 g, 0.216 mmol, 1.0 equiv) were dissolved in distilled toluene (2.0 mL) and dried overnight under vacuum. Acid washed molecular sieves AW 300 were activated under vacuum and added to the reagents. The mixture was dissolved in dry CH₂Cl₂ (2.5 mL), catalytic amount of TMSOTf (7.8 μ L, 0.0432 mmol, 0.2 equiv) was added under nitrogen at -20°C and the reaction mixture was stirred at the same temperature for 3h. Et₃N (20.0 μ L) was added and the mixture was diluted with CH₂Cl₂ and filtered through a Celite® pad. Evaporation of the solvent afforded a crude product (0.290 g), which was subjected to a flash chromatography. Elution with a 7:3 hexane/acetone mixture afforded the *O*-protected pseudomannobioside **18** (0.208 mg, 88% yield), pure as a white solid. m.p. 40-42°C. R_f = 0.22 (7:3 hexane/acetone); [α]_D²⁰ -23.0 (c 0.63, CHCl₃). FTIR (neat) ν 3350.1, 3294.9, 3069.3, 2961.0, 2875.4, 2106.4, 1724.0, 1601.0, 1450.7, 1259.8, 1094.9, 1065.8, 1026.6, 825.9, 707.9 cm⁻¹. ¹H NMR (250 MHz, CDCl₃) δ 8.01-8.16 (m, 5H, Ar), 7.92-8.00 (m, 2H, Ar), 7.70-7.90 (m, 2H, Ar), 7.03-7.69 (m, 26H, Ar), 6.04 (t, *J* = 9.5 Hz, 1H, H_{4'}), 5.85-5.94 (m, 2H, H_{2'}+H_{3'}), 5.45 (s, 1H, Hanomeric), 4.39-4.92 (m, 9H, benzylic + H_{5'} + H_{6'}a + H_{6'}b), 4.22 (d, *J* = 4.2 Hz, 1H, H₂), 3.78-3.86 (m, 2H, H₃ + H_{CH2CH2N3}), 3.68-3.75 (m, 1H, H₁), 3.49-3.65 (m, 3H, H_{CH2CH2N3}), 3.30-3.41 (m, 1H, H₄), 3.07-3.25 (m, 2H, H_{6a} + H_{6b}), 1.83-2.16 (m, 3H, H₅ + H_{5aa} + H_{5a β}).

¹³C NMR (CDCl₃) δ 166.31, 165.73, 165.52, 165.24, 138.96, 138.92, 138.59, 133.58, 133.27, 130.01, 129.89, 129.64, 129.37, 129.09, 128.69, 128.61, 128.44, 127.83, 127.64, 127.56, 98.90,

76.25, 75.11, 73.10, 70.78, 70.40, 70.13, 69.54, 67.99, 67.35, 63.39, 50.91, 37.71, 27.72.

(2-aminoethyl)-2-O-[2',3',4',6'-tetra-O-benzoyl- α -D-mannopyranosyl]-5a-carba- α -D-mannopyranoside (19).

Pseudomannobioside **18** (0.080 g, 0.073 mmol, 1.0 equiv) was dissolved in a 4:1 MeOH/anhydrous DMF mixture (2.0 mL) and 10% Pd-C (0.080 g) was added. The reaction mixture was hydrogenated (1 bar) at room temperature under hydrogen saturated atmosphere until reduction of the azide group and deprotection of the benzyl groups were achieved, monitoring by analytical TLC (8:2 CH₂Cl₂/MeOH). After 18 h the mixture was diluted with MeOH and filtered through a Celite® pad. The evaporation of the solvent afforded a crude reaction product (0.035 g) which was further diluted with MeOH and filtered off using syringe filter, to remove the residue coal. Evaporation of the solvent afforded a white solid, which was recrystallized from (*i*-Pr)₂O to yield pure 1,2-pseudomannobioside **19** (0.031 g, 53% yield), as a yellow solid: mp: 38-39 °C. *R*_f = 0.3 (8:2 CH₂Cl₂/MeOH + 0.1% Et₃N); [α]_D²⁰ -34.85 (*c* 0.68, MeOH). FTIR (neat) ν 3377.6, 3072.1, 2951.0, 2782.8, 1721.2, 1656.4, 1592.8, 1437.7, 1297.2, 1256.9, 1161.3, 1082.4, 1066.3, 1018.5, 857.5, 697.4 cm⁻¹. ¹H NMR (250 MHz, CD₃OD) δ 8.06-8.16 (m, 2H, Ar), 7.88-8.03 (m, 4H, Ar), 7.22-7.80 (m, 14H, Ar), 6.11 (t, *J* = 9.8 Hz, 1H, H4'), 5.89-5.97 (m, 1H, H2'), 5.84 (dd, *J* = 10.2, 3.2 Hz, 1H, H3'), 5.48 (d, *J* = 1.4 Hz, 1H, Hanomeric), 4.77 (dd, *J* = 13.4, 3.9 Hz, 1H, H5'), 4.47-4.58 (m, 2H, H6'a + H6'b), 4.23-4.26 (m, 1H, H2), 3.90-3.97 (m, 1H, H1) 3.45-3.89 (m, 6H, H3 + H4 + H6a + H6b + OCH₂), 3.07-3.12 (m, 2H, CH₂NH₂), 2.00-2.13 (m, 1H, H5), 1.72-1.89 (m, 2H, H5 α + H5 β). ¹³C NMR (63 MHz, CD₃OD) δ 167.53, 167.01, 166.79, 166.54, 134.78, 134.74, 134.57, 134.55, 131.12, 130.76, 130.71, 130.69, 130.60, 130.51, 130.30, 130.27, 129.84, 129.78, 129.63, 129.47, 101.30, 80.54, 78.24, 74.20, 72.33, 71.71, 71.46, 70.77, 68.31, 66.16, 64.34, 63.92, 40.91, 40.46, 27.79

(2-aminoethyl)-2-O-(α -D-mannopyranosyl)-5a-carba- α -D-mannopyranoside (5).

A solution 1M of MeONa in MeOH (65.0 μ L, 0.065 mmol, 1.5 equiv) was added to a solution of 1,2-pseudomannobioside **19** (0.034 g, 0.043 mmol, 1.0 equiv) in MeOH (0.8 mL). The reaction mixture was stirred for 12h monitoring by TLC (8:2 CH₂Cl₂/MeOH). The reaction mixture was diluted with MeOH and Amberlite IRC 50 was added until pH 7. The beads were filtered off and washed with MeOH, then, the filtrated solution was evaporated affording a crude reaction product (0.015 g). The solid product was dissolved in MeOH and filtered through a syringe filter. Evaporation of the solvent afforded a yellow solid, which was recrystallized from (*i*-Pr)₂O to yield fully *O*-deprotected 1,2-pseudomannobioside **5** (0.011 g, 70 % yield), pure as a pale yellow solid: mp: 103-105 °C. *R*_f = 0.15 (1:1 CH₂Cl₂/MeOH); [α]_D²⁰ +16.4 (*c* 1.14, MeOH). FTIR (neat) ν 3396.5, 2924.9, 2852.6, 2746.5, 2489.3, 1537.7, 1486.7, 1180.4, 1048.6, 1025.8 cm⁻¹. ¹H NMR (250 MHz, CD₃OD) δ 5.06 (d, *J* = 1.7 Hz, 1H, Hanomeric), 4.03-4.11 (m, 1H, CHO), 3.98 (dd, *J* = 3.2, 1.7 Hz, 1H, CHO), 3.42-3.93 (m, 12H, CHO), 3.13 (t, *J* = 5.1 Hz, 2H, CH₂NH₂), 1.88-1.99 (m, 1H, H5), 1.53-1.85 (m, 2H, H5 α + H5 β). ¹³C NMR (63 MHz, CD₃OD) δ 104.01, 96.65, 79.60, 78.05, 75.52, 74.19, 72.49, 71.83, 68.75, 66.97, 64.47, 63.19,

41.15, 40.46, 27.74. HRMS: (M +H⁺) found 384.1860; C₁₅H₃₀NO₁₀ requires 384.1870.

3,4,6-tri-O-acetyl-1,2-anhydro-5a-carba- β -D-mannopyranose (13).²⁵

β -Epoxide diol **11** (0.060g, 0.24 mmol, 1.0 equiv) was dissolved in EtOH (2.0 mL) and 10% Pd-C (0.010 g) was added. The reaction mixture was hydrogenated (1 bar) at room temperature under hydrogen saturated atmosphere overnight. The reaction mixture was then diluted with EtOH and filtered through a Celite® pad. The evaporation of the solvent afforded a crude reaction product which was further diluted with EtOH and filtered off using syringe filter, to remove the residue coal. Evaporation of the solvent afforded a crude reaction product (0.032 g) as a colorless liquid constituted by epoxy triol **12**, directly acetylated. Epoxy triol **12** (0.032 g, 0.20 mmol, 1.0 equiv) was dissolved in anhydrous pyridine (0.5 mL) and the reaction mixture was cooled at 0°C. Acetic anhydride (0.25 mL) was added and the reaction was stirred at room temperature overnight. Coevaporation of the reaction mixture with toluene afforded a crude product (0.049 g), which was subjected to flash chromatography. Elution with 1:1 hexane/AcOEt mixture afforded tri-*O*-acetyl- β -epoxide **13** (0.040 g, 70% yield), pure as a pale yellow oil. *R*_f = 0.26 (hexane/AcOEt 1:1); ¹H NMR (CDCl₃) δ 5.23 (dd, *J* = 8.7, 1.8 Hz, 1H, H3), 5.07-5.19 (m, 1H, H4), 4.05 (dd, *J* = 11.4, 4.9 Hz, 1H, H6), 3.85 (dd, *J* = 11.3, 3.1 Hz, 1H, H6'), 3.41 (dd, *J* = 3.9, 1.5 Hz, 1H, H1), 3.33 (t, *J* = 4.2 Hz, 1H, H2), 2.13-2.25 (m, 1H, H5), 2.10 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.01 (s, 3H, OAc), 1.88-1.97 (m, 2H, H5 α + H5 β). ¹³C NMR (CDCl₃) δ 171.11, 170.34, 170.02, 71.18, 70.01, 69.90, 63.90, 53.38, 35.72, 29.20, 21.00, 20.96, 20.92.

(2-azidoethyl)-3,4,6-tri-O-acetyl-5a-carba- α -D-mannopyranoside (15).

Tri-*O*-acetyl epoxide **13** (0.033 g, 0.114 mmol, 1.0 equiv) was dissolved in a 1.3 M solution of 2-azido-1-ethanol in CH₂Cl₂²⁵ (0.36 mL, 0.456 mmol, 4.0 equiv) and Cu(OTf)₂ (0.016 g, 0.045 mmol, 0.4 equiv) was added. The reaction mixture was stirred for 18 h at room temperature. Dilution with CH₂Cl₂ and evaporation of the washed (1:1 NaHCO₃/NH₄Cl mixture and brine) and dried (Na₂SO₄) organic solution afforded a crude reaction product (0.048 g) which was subjected to flash chromatography. Elution with a 1:1 hexane/AcOEt solution afforded the glycosyl acceptor **15** (0.035 g, 82% yield), pure as a pale yellow oil. *R*_f = 0.14 (1:1 hexane/AcOEt). [α]_D²⁰ +21.71 (*c* 0.35, CHCl₃). FTIR (neat) ν 3480.4, 2956.7, 2925.7, 2855.4, 2106.9, 1738.1, 1454.0, 1368.7, 1227.5, 1098.8, 1039.6, 801.0 cm⁻¹. ¹H NMR (250 MHz, CDCl₃) δ 5.23-5.34 (m, 1H, H3), 5.20 (dd, *J* = 9.5, 2.7 Hz, 1H, H4), 4.16-4.23 (m, 1H, H2), 4.11 (dd, *J* = 11.3, 4.9 Hz, 1H, H6), 3.94 (dd, *J* = 11.3, 4.9 Hz, 1H, H6'), 3.73-3.78 (m, 1H, H1), 3.70 (t, *J* = 5.0 Hz, 2H, CH₂N₃), 3.39 (d, *J* = 4.6 Hz, 1H, OCH₂), 3.35 (d, *J* = 4.6 Hz, 1H, OCH₂), 2.24-2.36 (m, 1H, H5), 2.08 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.03 (s, 3H, OAc), 1.86-1.94 (m, 2H, H5 α + H5 β). ¹³C NMR (CDCl₃) δ 171.13, 170.55, 169.90, 73.87, 69.71, 68.67, 63.93, 50.93, 35.19, 26.77, 21.08, 20.96.

(2-azidoethyl)-2-*O*-[2',3',4',6'-tetra-*O*-benzoyl- α -D-mannopyranosyl]-3,4,6-tri-*O*-acetyl-5a-carba- α -D-mannopyranoside (17).

Trichloroacetimidate **6**²¹ (0.047g, 0.064 mmol, 1.3 equiv) and carbamannoside **15** (0.019 g, 0.049 mmol, 1.0 equiv) were dissolved in distilled toluene (2.0 mL) and dried overnight under vacuum.

Acid washed molecular sieves AW 300 were activated under vacuum and added to the reagents. The mixture was dissolved in dry CH₂Cl₂ (1.0 mL) and a catalytic amount of TMSOTf (1.76 μ L, 0.010 mmol, 0.2 equiv) was added under nitrogen at -20°C and the reaction mixture was stirred at the same temperature for 20 minutes, monitoring by TLC (1:1 hexane/AcOEt). Et₃N (10.0 μ L) was added and the mixture was diluted with CH₂Cl₂ and filtered through a Celite® pad. Evaporation of the solvent afforded a crude product (0.034 g), which was subjected to a flash chromatography. Elution with a 1:1 hexane/AcOEt mixture as eluent afforded the *O*-protected pseudomannobioside **17** (0.025 g, 53% yield) pure as a pale yellow oil. *R*_f = 0.40 (1:1 hexane/AcOEt). [α]_D²⁰ -42.8 (*c* 1.7, CHCl₃).

¹H NMR (CDCl₃) δ 7.94-8.15 (m, 6H, Ar), 7.79-7.89 (m, 2H, Ar), 7.21-7.67 (m, 12H, Ar), 6.06 (t, 1H, *J* = 9.9 Hz, H4'), 5.92 (dd, 1H, *J* = 10.2, 3.1 Hz, H2'), 5.69 (dd, 1H, *J* = 2.9, 1.6 Hz, H3'), 5.36 (d, 1H, *J* = 10.1 Hz, H3), 5.32 (d, 1H, *J* = 1.6 Hz, Hanomeric), 5.26 (dd, 1H, *J* = 9.8, 2.8 Hz, H4), 4.69 (dd, 1H, *J* = 12.0, 2.5 Hz, H6'a), 4.50 (dd, 1H, *J* = 12.0, 5.4 Hz, H6'b), 4.36-4.45 (m, 1H, H5'), 4.31 (t, 1H, *J* = 3.2 Hz, H2), 4.17 (dd, 1H, *J* = 11.4, 5.7 Hz, H6a), 4.03 (dd, 1H, *J* = 11.4, 3.6 Hz, H6b), 3.73-3.80 (m, 1H, H1), 3.44-3.60 (m, 2H, CH₂N3), 3.13-3.36 (m, 2H, OCH₂), 2.21-2.45 (m, 1H, H5), 2.16 (s, 3H, OAc), 2.13 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.00 (dd, 2H, *J* = 8.4, 2.3 Hz, H5 $\alpha\alpha$ + H5 $\alpha\beta$). ¹³C NMR (CDCl₃) δ 171.37, 170.67, 170.06, 166.24, 165.81, 165.64, 165.31, 133.69, 133.39, 130.00, 129.86, 129.43, 129.19, 128.98, 128.78, 128.63, 128.46, 99.03, 76.32, 76.14, 72.44, 70.84, 69.96, 69.73, 69.26, 68.58, 67.45, 63.85, 63.41, 50.80, 35.40, 20.94.

(2-azidoethyl)-2-*O*-(α -D-mannopyranosyl)-5a-carba- α -D-mannopyranoside (4).

Compound **17** (0.025 g, 0.026 mmol, 1.0 equiv) was dissolved in MeOH (0.8 mL) and cooled at 0 °C. A freshly prepared 1.0 M solution of MeONa/MeOH (78 μ L, 0.078 mmol, 0.3 equiv) was added to the resulting solution and the reaction mixture was stirred for 12 h at room temperature. The mixture was then neutralized with an acidic Amberlite™ IR 120 H resin. The resin was then removed by filtration and repeatedly extracted with methanol. The combined filtrate was concentrated under vacuum to give a crude product, which was recrystallized from *i*-PrOH to yield pure glycoside **4** (0.010 g, yield 88%) as a white solid: mp: 85-88°C. *R*_f = 0.21 (1:1 CH₂Cl₂/MeOH). [α]₂₀^D -43.2 (*c* 0.36, MeOH) ¹H NMR (D₂O) δ 4.98 (s, 1H, Hanomeric), 4.04 (bs, 2H, H1 + H2), 3.95 – 3.50 (m, 12H, CHO, CH₂O, CH₂N3), 3.44 – 3.37 (m, 2H, OCH₂), 1.96 – 1.86 (m, 1H, H5), 1.80 – 1.54 (m, 2H, H5 $\alpha\alpha$ + H5 $\alpha\beta$). ¹³C NMR (D₂O, 0.1% CD₃CN) δ 101.70, 78.45, 75.15, 72.81, 71.49, 69.51, 69.23, 69.09, 66.77, 65.93, 61.30, 60.20, 49.57, 37.82, 25.40. HRMS: (M + Na⁺) found 432.1586; C₁₅H₂₇N₃O₁₀Na requires 432.1594.

Biological assays

Surface plasmon resonance analysis. DC-SIGN ECD production and purification: DC-SIGN extracellular domain (DC-SIGN ECD) construct was produced and purified as described previously.³¹

Surface Plasmon Resonance analysis: Surface plasmon resonance experiments were performed on a Biacore 3000 using a CM4 chip, functionalized at 5 μ L/min. BSA or BSA-Man were immobilized on flow cells using amine-coupling method. Fc1 was prepared as reference surface. Flow cell (Fc) 1 and 2 were activated with 50 μ L of a 0.2M EDC/ 0.05 M NHS mixture. After this step, Fc1 and Fc2 were respectively functionalized with bovine serum albumine (BSA) and mannosylated bovine serum albumine (BSA-Mannotriose, BSA-man α 1-3[man α 1-6]man, 12 glycosylated sites, , 60 μ g.mL⁻¹, Dextra laboratories). Then remaining activated groups of both cells were blocked with 30 μ L of 1 M ethanolamine. After blocking, the two Fc were treated with 5 μ L of 10 mM HCl to remove unspecific bound protein and 5 μ L of 50 mM EDTA to expose surface to regeneration protocol. Finally, 2381 RU and 1847 RU of BSA and BSA-Man were respectively immobilized on Fc1 and Fc2. The selected concentration was 20 μ M for DC SIGN ECD.

For inhibition studies, 20 μ M of DC-SIGN ECD mixed with increasing concentrations of inhibiting compounds were prepared in a running buffer composed of 25 mM Tris pH 8, 150 mM NaCl, 4 mM CaCl₂, 0.005% P20 surfactant, and 13 μ L of each sample was injected onto the surfaces at a 5 μ L/min flow rate. The resulting sensorgrams were reference surface corrected.

The DC-SIGN binding responses were extracted from sensorgrams, converted to percent residual activity values (*y*) with respect to lectin alone binding, and plotted against corresponding compound concentration. The 4-parameter logistic model (equation 1) was fitted to the plots, and the IC₅₀ values were calculated, from equation 2, using the values of fitted parameters (*R*_{hi}, *R*_{lo}, *A*₁ and *A*₂).

$$y = R_{hi} - \frac{R_{hi} - R_{lo}}{1 + \left(\frac{Conc}{A_1}\right)^{A_2}} \quad IC_{50} = A_1 \cdot \left(\left(\frac{R_{hi} - R_{lo}}{R_{hi} - 50} \right)^{\frac{1}{A_2}} - 1 \right)$$

Figure 4 Equation for percent residual activity values and for IC50 values

Acknowledgements

This work used the platforms of the Grenoble Instruct centre (ISBG ; UMS 3518 CNRS-CEA-UJF-EMBL), notably the MP3 and SPR platforms, with support from FRISBI (ANR-10-INSB-05-02) and GRAL (ANR-10-LABX-49-01) within the Grenoble Partnership for Structural Biology (PSB). V.Porkolab was supported by a grant from la Région Rhône-Alpes. F.Fieschi and A.Bernardi acknowledge for support from CM1102 COST Action. V. Di Bussolo acknowledges the University of Pisa (Progetti di Ricerca di Ateneo, PRA 2015 0015) for funding.

Notes and references

^a Dipartimento di Farmacia, Università di Pisa, Via Bonanno 33, 56126 Pisa, Italy.

^b Univ. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale, F-38044 Grenoble, France.

^c Dipartimento di Chimica, Università degli Studi di Milano, via Golgi 19, 20133 Milano, Italy

^d Dipartimento di Chimica e Chimica Industriale, Università di Pisa, Via Moruzzi 13, 56125 Pisa, Italy; E-mail: valeria.dibussolo@unipi.it.

† Electronic Supplementary Information (ESI) available: [NMR spectra of **4** and **5**, **10-18**; HRMS of **4** and **5**; sensorgrams and inhibition curves of **4**, **5** and of natural epitope Man α (1,2)Man]. See DOI:/

1. A. Imberty, A. Varrot, *Curr Opin Struct Biol*, 2008, **18**, 567-576.
2. R. A. Dwek, *Chem. Rev.* 1996, **96**, 683-720.
3. L. L. Kiessling, J.C. Grim, *Chem. Soc. Rev.* 2013, **42**, 4476-4491.
4. S. Cecioni, A. Imberty, S. Vidal, *Chem. Rev.* 2015, **115**, 525-561.
5. T. B. H. Geijtenbeek, R. Torensma, S. J. van Vliet, G. C. F. van Duijnhoven, G. J. Adema, Y. van Kooyk, G.C. Figdor, *Cell*, 2000, **100**, 575-585.
6. S. K. Wang, P. H. Liang, R.D. Astronomo, T. L. Hsu, S.-L. Hsieh, D. R. Burton, C. H. Wong, *PNAS*, 2008, **105**, 3690-3695.
7. M. J., Borrok, L. L. Kiessling, *J.Am.Chem.Soc.* 2007, **129**, 12780-12785.
8. K. C. A. Garber, K. Wangkanont, E. E. Carlson, L. L. Kiessling, *Chem. Commun.* 2010, **46**, 6747-6749.
9. S. L. Mangold, L. R. Prost, L. L. Kiessling, *Chem. Sci.* 2012, **3**, 772-777.
10. J. J. Reina, S. Sattin, D. Invernizzi, S. Mari, L. Martinez-Prats, G. Tabarani, F. Fieschi, R. Delgado, P. M. Nieto, J. Rojo, A. Bernardi, *ChemMedChem* 2007, **2(7)**, 1030-1036.
11. G. Timpano, G. Tabarani, M. Anderluh, D. Invernizzi, F. Vasile, D. Potenza, P.M. Nieto, J. Rojo, F. Fieschi, A. Bernardi, *ChemBioChem* 2008, **9(12)**, 1921-1930.
12. S. Sattin, A. Daggetti, M. Thepaut, A. Berzi, M. Sanchez-Navarro, G. Tabarani, J. Rojo, F. Fieschi, M. Clerici, A. Bernardi, *ACS Chem. Biol.* 2010, **5(3)**, 301-312.
13. M. Andreini, D. Doknic, I. Sutkeviciute, J.J. Reina, J. Duan, E. Chabrol, M. Thepaut, E. Moroni, F. Doro, L. Belvisi, J. Weiser, J. Rojo, F. Fieschi, A. Bernardi, *Org. Biomol. Chem.* 2011, **9(16)**, 5778-5786.
14. J. Luczkowiak, S. Sattin, I. Sutkeviciute, J.J. Reina, M. Sanchez-Navarro, M. Thepaut, L. Martinez-Prats, A. Daggetti, F. Fieschi, R. Delgado, A. Bernardi, J. Rojo, *Bioconjugate Chem.* 2011, **22(7)**, 1354-1365.
15. A. Berzi, J. J. Reina, R. Ottria, I. Sutkeviciute, P. Antonazzo, M. Sanchez-Navarro, E. Chabrol, M. Biasin, D. Trabattoni, I. Cetin, J. Rojo, F. Fieschi, A. Bernardi, M. Clerici, *AIDS* 2012, **26(2)**, 127-137.
16. N. Obermajer, S. Sattin, C. Colombo, M. Bruno, U. Svajger, M. Anderluh, A. Bernardi, *Molecules Molecular Diversity* 2011, **15(2)**, 347-360.
17. N. Varga, I. Sutkeviciute, C. Guzzi, J. McGeagh, I. Petit-Haertlein, S. Gugliotta, J. Weiser, J. Angulo, F. Fieschi, A. Bernardi, *Chem. Eur J.* 2013, **19(15)**, 4786-4797.
18. O. Martinez-Avila, K. Hijazi, M. Marradi, C. Clavel, C. Campion, C. Kelly, C.; Penades, S. *Chem. Eur. J.* 2009, **15(38)**, 9874-9888.
19. M. Thepaut, C. Guzzi, I. Sutkeviciute, S. Sattin, R. Ribeiro-Viana, N. Varga, E. Chabrol, J. Rojo, A. Bernardi, J. Angulo, P. M. Nieto, F. Fieschi, *J. Am. Chem. Soc.* 2013, **135(7)**, 2518-2529.
20. S. Mari, H. Posteri, G. Marcou, D. Potenza, F. Micheli, F. J. Canada, J. Jimenez-Barbero, A. Bernardi, *Eur. J. Org. Chem.* 2004, **24**, 5119-5125.
21. D. J. Lee, R. Kowalczyk, V. J. Muir, P. M. Rendle, M. A. Brimble, *Carbohydr. Res.* 2007, **342(17)**, 2628-2634.
22. I. Frau, V. Di Bussolo, L. Favero, M. Pineschi, P. Crotti, *Chirality* 2011, **23(9)**, 820-826.
23. A. H. Hoveyda, D. A. Evans, G. C. Fu, *Chem. Rev.* 1993, **93(4)**, 1307-70.
24. S. Ogawa, T. Tonegawa, *Carbohydr. Res.* 1990, **204**, 51-64.
25. V. W.-F. Tai, P. -H. Fung, Y.-S. Wong, T. K. M. Shing, *Tetrahedron:Asymmetry* 1994, **5(7)**, 1353-1362.
26. Y. Dong, X. Liang, H. Yuan, S. Qi, F. Chen, D. Wang, *Green Chem.* 2008, **10(9)**, 990-994.
27. A. Bernardi, D. Arosio, L. Manzoni, F. Micheli, A. Pasquarello, P. Seneci, *J. Org. Chem.* 2001, **66(19)**, 6209-6216.
28. S. Ogawa, S. Sasaki, H. Tsunoda, *Chem. Lett.* 1993, **9**, 1587-1590.
29. J. Frigell, I. Cumpstey, *Beilstein J. Org. Chem.* 2010, **6**, 1127-1131.
30. G. Timpanaro, G. Tabarani, M. Anderluh, D. Invernizzi, F. Vasile, D. Potenza, P. M. Nieto, J. Rojo, F. Fieschi, A. Bernardi, *ChemBioChem* 2008, **9**, 1921-1930.
31. G. Tabarani, M. Thepaut, D. Stroebel, C. Ebel, C. Vivès, P. Vachette, D. Durand, F. Fieschi, 2009, **284(32)**, 21229-21240.